Vir Biotechnology SVP Executes Rule 10b5-1 Sale; Company Posts Strong Phase 2 Hepatitis Delta Data and Strikes Norgine Deal
Brent Sabatini, SVP and Chief Accounting Officer at Vir Biotechnology (VIR), completed an automatic sale of 1,530 shares on February 13, 2026, under a pre-arranged Rule 10b5-1 plan to satisfy tax withholding tied to restricted stock unit vesting. The transaction totaled $11,918 at $7.79 per share, leaving Sabatini with 47,872 shares. Separately, Vi…